Early-stage lung cancer surgery is not the finish line. It is the beginning of a second race, and the ADAURA trial just told us who wins it.
In September 2026, AstraZeneca presented the 8-year exploratory overall survival (OS) update from the Phase III ADAURA trial at the World Conference on Lung Cancer. The data were published simultaneously in the Journal of Thoracic Oncology. The numbers, already striking at three and five years, are now definitive: adjuvant osimertinib (Tagrisso) reduces the risk of death by 47 percent in patients with resected Stage II-IIIA EGFR-mutated non-small cell lung cancer. This is the longest survival follow-up ever reported from a global Phase III trial in this setting.
For thoracic oncologists, radiation oncologists, and health system leaders, the question is no longer whether osimertinib belongs in the adjuvant setting. That question is closed. The question is whether your multidisciplinary workflow is built to actually deliver the benefit these numbers …



